A Standardized Composite Clinical Score for Inhaled Corticosteroids Taper Studies in Asthma
Current asthma treatment guidelines recommend a reduction in inhaled corticosteroid (ICS) doses when appropriate. However, no standardized taper protocols are available to guide ICS tapering in clinical trials or in general practice. This study was designed to determine the safety and effectiveness of tapering the ICS dose in asthmatic patients using specific tapering and rescue protocols. Twenty-two clinically stable asthmatic patients on moderate-to-high doses of ICS were studied. Patients were given either montelukast (10 mg daily) or placebo for 8 weeks and evaluated every 2 weeks. A composite clinical score (0 to 3) comprising lung function, symptoms, and “as-needed” β-agonist use was calculated at each visit. Based on this score, the ICS dose was either tapered, increased, or maintained at each visit. The minimum ICS dose that maintained clinical stability was defined as the last tolerated dose.
The results showed that mean percent change from baseline (1523 μg/day, SD = 536) in the last tolerated dose was 49.8% (SD = 37.4). Sixteen patients tolerated at least one taper; of these, 12 tolerated 2 or more tapers. Seven patients tapered completely off ICS. In contrast, six patients did not tolerate a single taper. Ten patients required rescue from mild worsening with an increase in ICS dose, of which nine were successful and one achieved stability with a second ICS dose increase two weeks later. Overall, patients remained clinically stable during tapering. It is concluded that tapering of ICS guided by the clinical composite score was well tolerated. The rescue protocol was effective in restabilizing patients. The results of this study thus support the use of a composite clinical score in larger clinical trials.
Key WordsInhaled corticosteroid Asthma Steroid tapering Composite clinical score Steroid sparing
Unable to display preview. Download preview PDF.
- 3.National Heart, Lung, and Blood Institute. Expert Panel Report 2: Guidelines for the Diagnosis and Management of Asthma. Bethesda, MD: National Heart, Lung, and Blood Institute: Lund 1997. NIH Publication No. 97–4051.Google Scholar
- 5.Zhang J, Song C, Reiss TF. Development and validation of a sensitive measure of worsening asthma. Am J Resp Crit Care Med. 1997;155:A892.Google Scholar
- 7.Lofdahl C-G, Reiss TF, Leff JA, Israel E, Noonan MJ, Finn AF, Seidenberg BC, Capizzi T Kundu S, Godard P. Randomized, placebo-controlled trial of effect of a leukotriene receptor antagonist, on tapering inhaled corticosteroids in asthmatic patients. Br Med J. 1999;318–87–90.Google Scholar
- 8.Price DB, Rouleau MY, Fletcher CP, Patel P, Olivenstein R, Myhr L, Virchow JC, Aitchison WRC, Omenaas ER, Dellea PS, Laurenzi M, Leff JA. Use of Montelukast in tapering inhaled corticosteroid therapy: An open-label, 48-week trial. Current Therapeutic Research; 2002.Google Scholar